form8_k101409.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported) October 14, 2009
Progenics
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-23143
|
|
13-3379479
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
777
Old Saw Mill River Road, Tarrytown, New York
|
|
10591
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code (914)
789-2800
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other Events.
Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has entered into an
agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) under
which Progenics is regaining all worldwide rights to the RELISTOR®
franchise from Wyeth Pharmaceuticals, which Progenics had previously licensed to
Wyeth Pharmaceuticals. Progenics will assume full control of future
development and commercialization of subcutaneous RELISTOR after a one-year
transition, and will immediately take over ongoing development of the oral form
of the drug.
A copy of
Progenics’ press release containing additional information about the agreement
is attached hereto as Exhibit 99.1 and the information contained therein is
incorporated by reference into this Item 8.01 of this Current Report on Form
8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No. Description
99.1
|
Press
Release dated October 14, 2009.
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
PROGENICS
PHARMACEUTICALS, INC.
By: /s/
ROBERT A.
MCKINNEY
Robert
A. McKinney
Chief Financial Officer, Senior Vice President,
Finance & Operations and Treasurer
Date: October
14, 2009